KMDA
Kamada Ltd (KMDA)
Healthcare • NASDAQ • $8.55+3.51%
- Symbol
- KMDA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $8.55
- Daily Change
- +3.51%
- Market Cap
- $494.33M
- Trailing P/E
- 24.43
- Forward P/E
- 14.41
- 52W High
- $9.35
- 52W Low
- $6.50
- Analyst Target
- $13.00
- Dividend Yield
- +2.93%
- Beta
- 0.20
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FO…
Company websiteResearch KMDA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.